This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demidenko, Z. N. Articles by Blagosklonny, M. V. Search for Related Content PubMed PubMed Citation Articles by Demidenko, Z. N. Articles by Blagosklonny, M. V.

Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor

Brander Cancer Research Institute and Department of Medicine, New York Medical College, Valhalla, New York

Flavopiridol (FP) inhibits gene expression and causes apoptosis, and these effects cannot be explained by inhibition of cyclin-dependent kinases that govern cell cycle. The simple and established notion that FP is an inhibitor of transcription predicts its effects. Because Mdm-2 targets p53 for degradation, FP, as predicted, dramatically induced p53 by inhibiting Mdm-2. Once p53 was induced, restoration of transcription (by removal of FP) resulted in superinduction of p21 and Mdm-2. Similarly, low concentrations of FP (50 nM) induced p21 and Mdm-2 because of their initial down-regulation. A sustained decrease of Mdm-2/p21 expression and accumulation of p53 coincided with near-maximal cytotoxicity of FP at concentrations >100 nM. Induction of p53 was a marker, not a cause, of cytotoxicity. FP caused rapid apoptosis (caspase-dependent cell death) in p53-null leukemia cells. In these cells, FP-induced apoptosis was converted to growth arrest by inhibitors of caspases. In apoptosis-reluctant A549 and PC3M cancer cells, FP inhibited cell proliferation but did not cause apoptosis. Like typical inhibitors of transcription, FP sensitized cells to apoptotic stimuli, allowing tumor necrosis factor to cause rapid and massive apoptosis in otherwise apoptosis-reluctant cells. We discuss that, as a reversible inhibitor of transcription, FP can be used clinically in novel rational drug combinations.

This article has been cited by other articles:

				D. Y. Lim, Y. Jeong, A. L. Tyner, and J. H. Y. Park Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G66 - G75. [Abstract] [Full Text] [PDF]

				G. I. Shapiro Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783. [Abstract] [Full Text] [PDF]

				S. K. Radhakrishnan and A. L. Gartel A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res., March 15, 2006; 66(6): 3264 - 3270. [Abstract] [Full Text] [PDF]

				D. Cai, K. F. Byth, and G. I. Shapiro AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9 Cancer Res., January 1, 2006; 66(1): 435 - 444. [Abstract] [Full Text] [PDF]

				D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, and S. R. Green Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II-Dependent Transcription and Down-regulation of Mcl-1 Cancer Res., June 15, 2005; 65(12): 5399 - 5407. [Abstract] [Full Text] [PDF]

				L. M. Lashinger, K. Zhu, S. A. Williams, M. Shrader, C. P.N. Dinney, and D. J. McConkey Bortezomib Abolishes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance via a p21-Dependent Mechanism in Human Bladder and Prostate Cancer Cells Cancer Res., June 1, 2005; 65(11): 4902 - 4908. [Abstract] [Full Text] [PDF]

				Z. N. Demidenko, D. Halicka, J. Kunicki, J. A. McCubrey, Z. Darzynkiewicz, and M. V. Blagosklonny Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel Cancer Res., May 15, 2005; 65(10): 4401 - 4407. [Abstract] [Full Text] [PDF]

				S. Najmi, R. Korah, R. Chandra, M. Abdellatif, and R. Wieder Flavopiridol Blocks Integrin-Mediated Survival in Dormant Breast Cancer Cells Clin. Cancer Res., March 1, 2005; 11(5): 2038 - 2046. [Abstract] [Full Text] [PDF]